Search

Your search keyword '"Kos Kudla, B"' showing total 175 results
Start Over Author "Kos Kudla, B"
175 results on '"Kos Kudla, B"'

2. Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.

Author

Ambrosini, V, Caplin, M, Castaño, JP, Christ, E, Denecke, T, Deroose, CM, Dromain, C, Falconi, M, Grozinsky-Glasberg, S, Hicks, RJ, Hofland, J, Kjaer, A, Knigge, UP, Kos-Kudla, B, Koumarianou, A, Krishna, B, Lamarca, A, Pavel, M, Reed, NS, Scarpa, A, Srirajaskanthan, R, Sundin, A, Toumpanakis, C, Prasad, V, Ambrosini, V, Caplin, M, Castaño, JP, Christ, E, Denecke, T, Deroose, CM, Dromain, C, Falconi, M, Grozinsky-Glasberg, S, Hicks, RJ, Hofland, J, Kjaer, A, Knigge, UP, Kos-Kudla, B, Koumarianou, A, Krishna, B, Lamarca, A, Pavel, M, Reed, NS, Scarpa, A, Srirajaskanthan, R, Sundin, A, Toumpanakis, C, and Prasad, V

Abstract

Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%). In 3/15 statements, agreement was higher than 75%: (i) FDG was considered useful in NET, irrespective of grade, in case of mis-matched lesions (detectable on diagnostic CT but negative/faintly positive on SST PET/CT), especially if PRRT is contemplated (80%); (ii) in NET G3 if curative surgery is considered (82%); and (iii) in NEC prior to surgery with curative intent (98%). FDG use in NET G3, even in the presence of matched lesions, as a baseline for response assessment was favoured by 74%. Four statements obtained more than 60% consensus: (i) FDG use in NET G3 if locoregional therapy is considered (65%); (ii) in neuroendocrine carcinoma before initiating active therapy as a baseline for response assessment (61%); (iii) biopsy to re-assess tumour grade prior to a change in therapeutic management (68%) upon detection of FDG-positivity on the background of a prior G1-2 NET; (iv) 67% were in favour to reconsider PRRT to treat residual SST-positive lesions after achieving complete remission on FDG of the SST-negative disease component. Multidisciplinary opinion broadly supports the use of FDG PET/CT for characterisation of disease biology and to guide treatment selection across a range of indications, despite the lack of full consensus in many situations. This may reflect existing clinical access due to lack of reimbursement or experience with this investigation, which should be add

Published
2024

3. MODIFIED HISTOPATHOLOGICAL GRADING OPTIMIZES PREDICTION OF SURVIVAL OUTCOMES IN SMALL INTESTINAL NEUROENDOCRINE TUMOURS

Author

Daskalakis, Kosmas, Tsoli, M., Wallin, Göran, Kogut, A., Srirajaskanthan, R., Giovos, G., Weickert, M. O., Kos-Kudla, B., Kaltsas, G., Daskalakis, Kosmas, Tsoli, M., Wallin, Göran, Kogut, A., Srirajaskanthan, R., Giovos, G., Weickert, M. O., Kos-Kudla, B., and Kaltsas, G.

Abstract

Background: We aimed to identify optimal grading Ki-67 cut-offs to delineate differences in prognosis of patients with small intestinal neuroendocrine tumours (SI-NETs) in terms of overall- and event-free survival rates. Methods: We included 551 patients with SI-NETs diagnosed from June 15th, 1993, through March 8th, 2021, identified using the SI-NET databases from five European referral centers. Results: Median age at baseline was 62.3(17-90) years; 252 patients were women (45.7%). All tumours were well-differentiated; 326 were G1 tumours (59.2%), 169 G2(30.7%), only 8 G3(1.5%), while 48 tumourswere of unspecified grade (8.7%). The median Ki67 was 2%(1-70%). 247 patients(44.8%) had distant metastases at baseline (stage IV), 217locoregional disease (41.1%; stage III), whereas 29(7.1%) and 25(4.5%) presented at stages II and I, respectively. Within a mean(SD) follow-up of 51.5(52.9) months, 94 patients(17.1%) died, whereas overall 188 experienced disease recurrence, progression and/or death(34.1%). The median OS was 214.7(95%CI: 152.7-276.6) months and the median EFS was 79.8(95%CI: 68.2-91.5) months, respectively. In multivariable Cox-regression OS analysis, age (HR=1.07, 95%CI: 1.04-1.09; p<0.001), Charlson Comorbidity Index(HR=1.1, 95%CI: 1.03-1.17; p=0.006) and the proposed modified histopathological Ki67 grading system(K67:5-10% group: HR=2.4, 95%CI: 1.3-4.5; p=0.007 and K67≥10% group: HR=5.1, 95%CI: 2.9-9.2; p<0.001) were independent predictors for death. Pertinent EFS analysis, confirmed age(HR=1.04, 95%CI: 1.02-1.05;p<0.001) and the proposed modified histopathological Ki67 grading system(K67≥10% group: HR=4; 95%CI:2.5-6.2;p<0.001) as independent predictors for recurrence, progression and/or death. Conclusions: Ki-67 proliferation index is an independent predictor of EFS and OS. A modified site-specific histopathological grading system applying Ki-67 cut-offs of 5% and 10% seems more optimal to predict differences in SI-NET patient prognosis

Published
2024
Full Text
View/download PDF

6. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors

Author

Borbath, I., Pape, U. -F., Deprez, P. H., Bartsch, D. K., Caplin, M., Falconi, M., Garcia-Carbonero, R., Grozinsky-Glasberg, S., Jensen, R. T., Arnold, R., Ruszniewski, P., Toumpanakis, C., Valle, J. W., O'Toole, D., Belli, S. H., Castano, J. P., Chen, J., Costa, F. P., Couvelard, A., de Herder, W. W., Deroose, C. M., Dromain, C., Faggiano, A., Falkerby, J., Fazio, N., Frilling, A., Grande, E., Hand, P., Hicks, R. J., Horsch, D., Howe, J. R., Kloppel, G., Kolarova, T., Kos-Kudla, B., Koumarianou, A., Krejs, G. J., Krenning, E. P., Krishna, B. A., Leyden, S., Masui, T., Niederle, B., Nieveen van Dijkum, E. J., Oberg, K., Pavel, M., Perren, A., Prasad, V., Ramage, J. K., Reed, N. S., Rindi, G., Gemelli, A., Rinke, A., Rothmund, M., Singh, S., Sundin, A., Velthuysen, M. F. V., Verslype, C., Vullierme, M. P., Welin, S., Wiedenmann, B., Zhao, H., Graduate School, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Cellular and Molecular Neuroscience, Neuroendocrine Tumors, Endocrinology, neuroendocrine neoplasms, Endocrine and Autonomic Systems, Endocrinology, Diabetes and Metabolism, Humans, Endoscopy, endoscopy, standardised reporting
Abstract

Despite efforts from various endoscopy societies, reporting in the field of endoscopy remains extremely heterogeneous. Harmonisation of clinical practice in endoscopy has been highlighted by application of many clinical practice guidelines and standards pertaining to the endoscopic procedures and reporting are underlined. The aim of the proposed "standardised reporting" is to (1) facilitate recognition of gastrointestinal neuroendocrine neoplasms (NEN) on initial endoscopy, (2) to enable interdisciplinary decision making for treatment by a multidisciplinary team, (3) to provide a basis for a standardised endoscopic follow-up which allows detection of recurrence or progression reliably, (4) to make endoscopic reports on NEN comparable between different units, and (5) to allow research collaboration between NEN centres in terms of consistency of their endoscopic data. The ultimate goal is to improve disease management, patient outcome and reduce the diagnostic burden on the side of the patient by ensuring the highest possible diagnostic accuracy and validity of endoscopic exams and possibly interventions.

Published
2022

7. ENETS consensus guidelines for synoptic reporting of radiology studies

Author

Dromain, C, Vullierme, M-P, Hicks, RJ, Prasad, V, O'Toole, D, de Herder, WW, Pavel, M, Faggiano, A, Kos-Kudla, B, Oberg, K, Krejs, GJ, Grande, E, Niederle, B, Sundin, A, Dromain, C, Vullierme, M-P, Hicks, RJ, Prasad, V, O'Toole, D, de Herder, WW, Pavel, M, Faggiano, A, Kos-Kudla, B, Oberg, K, Krejs, GJ, Grande, E, Niederle, B, and Sundin, A

Abstract

This expert consensus document represents an initiative by the European Neuroendocrine Tumor Society (ENETS) to provide guidance for synoptic reporting of radiological examinations critical to the diagnosis, grading, staging and treatment of neuroendocrine neoplasms (NENs). Template drafts for initial tumor staging and follow-up by computed tomography (CT) and magnetic resonance imaging (MRI) were established, based on existing institutional and organisational reporting templates relevant for NEN imaging, and applying the RadLex lexicon of radiological information (Radiological Society of North America), for consistency regarding the radiological terms. During the ENETS Scientific Advisory Board meeting 2018, the template drafts were subject to iterative interdisciplinary discussions among experts in imaging, surgery, gastroenterology, oncology and pathology. Members of the imaging group stated a strong preference for a combination of limited and standardised options by way of drop-down menus. Separate templates were produced for the initial work-up and for follow-up, respectively. To provide a detailed description of the radiological findings of the primary tumor and its local extension and spread, different templates were developed for bronchial, pancreatic and gastrointestinal NENs for CT and MRI, respectively. Each template was structured in 10 sections: clinical details, comparative imaging modality, acquisition technique, primary tumor findings, regional lymph node metastases, distant metastases, TNM classification, reference lesions according to RECIST 1.1, additional findings and conclusion. Two templates were developed for follow-up, for CT and MRI, respectively, and were specifically focused on assessment of therapy response. These included a qualitative response assessment, such as decrease of vascularisation and presence of necrosis, and a quantitative assessment according to RECIST 1.1 and the modified RECIST (mRECIST) for assessing tumor response follo

Published
2022

8. Unmet Needs in Appendiceal Neuroendocrine Neoplasms

Author

Toumpanakis, C, Fazio, N, Janson, ET, Horsch, D, Pascher, A, Reed, N, O'Toole, D, van Dijkum, EN, Partelli, S, Rinke, A, Kos-Kudla, B, Costa, F, Pape, UF, Grozinsky-Glasberg, S, Scoazec, JY, Detlef, B, Rudolf, A, Eric, B, Lisa, B, Ivan, B, Jaume, C, Martyn, C, Jie, C, Frederico, C, Anne, C, Jaroslaw, BC, de Herder, W.W., Massimo, F, Jenny, F, Nicola, F, Diego, F, Andrea, F, Rocio, GC, Simona, G, Vera, G, Ashley, G, Dieter, H, Robert, J, Gregory, K, Gunter, K, Peter, KU, Beata, KK, Guenter, JK, Krenning, EP, Matthew, K, Steven, WJL, Elisabeth, NV, Manuel, OJ, Dermot, O, Ulrich-Frank, P, Di Stefano, P, Ellen, PM, Marc, P, John, R, Nicholas, R, Guido, R, Anja, R, Philippe, R, Halfdan, S, Anders, S, Jean-Yves, S, Babs, GT, Eva, TJ, Christos, T, Juan, V, Marie-Pierre, V, Staffan, W, Bertram, W, Internal Medicine, ENETS 2016 Munich Advisory Board, Toumpanakis, C., Fazio, N., Tiensuu Janson, E., Horsch, D., Pascher, A., Reed, N., O'Apostoole, D., Nieveen Van Dijkum, E., Partelli, S., Rinke, A., Kos-Kudla, B., Costa, F., Pape, U. -F., Grozinsky-Glasberg, S., and Scoazec, J. -Y.

Subjects
medicine.medical_specialty, Biomedical Research, Critical approach, Neuroendocrine Tumors/diagnosis, Endocrinology, Diabetes and Metabolism, Guidelines as Topic, 030209 endocrinology & metabolism, Aggressive disease, Appendix, 030218 nuclear medicine & medical imaging, Unmet needs, Biomedical Research/trends, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Internal medicine, Epidemiology, medicine, Humans, Intensive care medicine, Appendiceal neuroendocrine neoplasm, Appendiceal Neoplasms/diagnosis, Endocrine and Autonomic Systems, business.industry, Clinical course, Right hemicolectomy, Retrospective cohort study, Prognosis, Carcinoid, Neuroendocrine tumour, Neuroendocrine Tumors, Appendiceal Neoplasms, Human medicine, Appendicectomy, business
Abstract

Appendiceal neuroendocrine neoplasms (ANEN) are mostly discovered coincidentally during appendicectomy and usually have a benign clinical course; thus, appendicectomy alone is considered curative. However, in some cases, a malignant potential is suspected, and therefore additional operations such as completion right hemicolectomy are considered. The existing European Neuroendocrine Tumour Society (ENETS) guidelines provide useful data about epidemiology and prognosis, as well as practical recommendations with regards to the risk factors for a more aggressive disease course and the indications for a secondary operation. However, these guidelines are based on heterogeneous and retrospective studies. Therefore, the evidence does not seem to be robust, and there are still unmet needs in terms of accurate epidemiology and overall prognosis, optimal diagnostic and follow-up strategy, as well as identified risk factors that would indicate a more aggressive surgical approach at the beginning and a more intense follow-up. In this review, we are adopting a critical approach of the ENETS guidelines and published series for ANEN, focusing on the above-noted “grey areas”.

Published
2019

16. THE EFFECT OF PROPHYLACTIC RIGHT HEMICOLECTOMY ON SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH WELL-DIFFERENTIATED APPENDICEAL NEUROENDOCRINE NEOPLASMS

Author

Kaltsas, G., Alexandraki, K. I., Poulia, K. A., Grozinsky-Glasberg, S., Pizanias, M., Srirajaskanthan, R., Kogut, A., Kos-Kudla, B., Ferreira, C., Weickert, M. O., Daskalakis, Kosmas, Kaltsas, G., Alexandraki, K. I., Poulia, K. A., Grozinsky-Glasberg, S., Pizanias, M., Srirajaskanthan, R., Kogut, A., Kos-Kudla, B., Ferreira, C., Weickert, M. O., and Daskalakis, Kosmas

Abstract

Background: Long-term outcomes, including health-related quality of life (HRQoL) issues are understudied in patients with well-differentiated ppendiceal neuroendocrine neoplasms (WD-ANENs). We aimed to evaluate the validity of currently applied criteria for completion prophylactic right hemicolectomy (pRHC) and determine its association with patient outcomes. Methods: This cohort study included patients with WD-ANENs from five European Centers of Excellence for neuroendocrine tumors. Eligible patients were divided between those who underwent appendectomy alone and those who underwent pRHC. HRQoL EORTCqlqc30 questionnaires and cross-sectional imaging data were prospectively collected. Results: The 166 patients included 119 women (71.2%). Mean age was 31 ± 16 years. Mean follow-up was 51 ± 54 months. Most patients (152[92%]) had tumors≤20 mm. Fifty-eight patients (34.9%) underwent pRHC that was unnecessary in 65.5%(38/58); and in 79.1%(34/43) of tumors≤20 mm. In multivariable analysis, tumor size>20 mm was the only independent predictor for lymph node (LN) positivity(p = 0.021). No disease-specific mortality was reported. Three patients developed recurrence (n = 2inthepRHC group vs. n = 1 in the appendectomy group;p = 0.263). Although global HRQol was not significantly depreciated in patients undergoing pRHC compared to appendectomy alone (median scores 0.79[0.25-1] vs. 0.83[0.08-1], respectively; p = 0.738), impaired social functioning (p = 0.016), diarrhea (p = 0.003) and financial difficulties (0.024) were more frequently reported in the pRHC group. Furthermore, physical-(p = 0.066) and role functioning (p = 0.055), as well as constipation issues(p = 0.072) emerged in the pRHC group with marginal significance. Conclusion: pRHC in WD-ANENs comes at a high rate of unnecessary procedures, functional HRQoL issues and diarrhoea. LN positivity at pRHC may lack prognostic significance, as no disease-specific mortality and scarce recurrence was evident in this series. T

Published
2020

26. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Author

O'Toole, D., Grossman, A., Gross, D., Fave, G. D., Barkmanova, J., O'Connor, J., Pape, U. F., Plöckinger, U., Åkerström, G., Annibale, B., Arnold, R., Bajetta, E., Chen, Y. J., Costa, F., Couvelard, A., Davar, J., Herder, W. D., Eriksson, B., Falconi, M., Ferone, D., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
Endocrinology, Diabetes and Metabolism, Diagnostic accuracy, insulinoma, Neuroendocrine tumors, Bioinformatics, secretin, 0302 clinical medicine, Endocrinology, immune system diseases, cancer diagnosis, conference paper, Biochemical markers, biology, Urinary 5-hydroxyindoleacetic acid, Chromogranin A, Fasting, Hydroxyindoleacetic Acid, Diabetes and Metabolism, Neuroendocrine Tumors, priority journal, 030220 oncology & carcinogenesis, diagnostic accuracy, 5 hydroxyindoleacetic acid, neuroendocrine tumor, hormones, hormone substitutes, and hormone antagonists, Neuroendocrine tumor test, musculoskeletal diseases, medicine.medical_specialty, Standard of care, MEDLINE, 610 Medicine & health, 030209 endocrinology & metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Patient information, Internal medicine, gastrin, medicine, Humans, biochemistry, human, Insulinoma, Gastrinoma, gastrinoma, Endocrine and Autonomic Systems, business.industry, practice guideline, biochemical marker, chromogranin A, hypoglycemia, patient information, medicine.disease, body regions, biology.protein, 570 Life sciences, Biomarkers, business
Abstract

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Published
2017
Full Text
View/download PDF

27. Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Lipinski M., Rydzewska G., Foltyn W., Andrysiak-Mamos E., Baldys-Waligorska A., Bednarczuk T., Blicharz-Dorniak J., Bolanowski M., Boratyn-Nowicka A., Borowska M., Cichocki A., Cwikla J. B., Falconi M., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., Jarzab B., Junik R., Kajdaniuk D., Kaminski G., Kolasinska-Cwikla A., Kowalska A., Krol R., Krolicki L., Kunikowska J., Kusnierz K., Lampe P., Lange D., Lewczuk-Myslicka A., Lewinski A., Londzin-Olesik M., Marek B., Nasierowska-Guttmejer A., Nowakowska-Dulawa E., Pilch-Kowalczyk J., Poczkaj K., Rosiek V., Ruchala M., Sieminska L., Sowa-Staszczak A., Starzynska T., Steinhof-Radwanska K., Strzelczyk J., Sworczak K., Syrenicz A., Szawlowski A., Szczepkowski M., Wachula E., Zajecki W., Zemczak A., Zgliczynski W., Kos-Kudla B., Lipinski, M., Rydzewska, G., Foltyn, W., Andrysiak-Mamos, E., Baldys-Waligorska, A., Bednarczuk, T., Blicharz-Dorniak, J., Bolanowski, M., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nowakowska-Dulawa, E., Pilch-Kowalczyk, J., Poczkaj, K., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Strzelczyk, J., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zemczak, A., Zgliczynski, W., and Kos-Kudla, B.

Subjects
Male, Duodenum, Stomach, Disease Management, Guidelines, Medical Oncology, Neuroendocrine Tumors, Endocrinology, Duodenal Neoplasms, Stomach Neoplasms, Neuroendocrine neoplasms, Gastrinoma, Humans, Female, Therapy, Poland, Diagnostics, Societies, Medical
Abstract

This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis, and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological, and localisation diagnoses. The principles of treatment are discussed, including endoscopic, surgical, pharmacological, and radionuclide treatments. Finally, there are also recommendations on patient monitoring.

Published
2017

28. Neuroendocrine neoplasms of the small intestine and appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Bednarczuk T., Bolanowski M., Zemczak A., Baldys-Waligorska A., Blicharz-Dorniak J., Boratyn-Nowicka A., Borowska M., Cichocki A., Cwikla J. B., Falconi M., Foltyn W., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., Jarzab B., Junik R., Kajdaniuk D., Kaminski G., Kolasinska-Cwikla A., Kowalska A., Krol R., Krolicki L., Kunikowska J., Kusnierz K., Lampe P., Lange D., Lewczuk-Myslicka A., Lewinski A., Lipinski M., Londzin-Olesik M., Marek B., Nasierowska-Guttmejer A., Nowakowska-Dulawa E., Palucki J., Pilch-Kowalczyk J., Rosiek V., Ruchala M., Sieminska L., Sowa-Staszczak A., Starzynska T., Steinhof-Radwanska K., Strzelczyk J., Sworczak K., Syrenicz A., Szawlowski A., Szczepkowski M., Wachula E., Zajecki W., Zgliczynski W., Kos-Kudla B., Bednarczuk, T., Bolanowski, M., Zemczak, A., Baldys-Waligorska, A., Blicharz-Dorniak, J., Boratyn-Nowicka, A., Borowska, M., Cichocki, A., Cwikla, J. B., Falconi, M., Foltyn, W., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Lipinski, M., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nowakowska-Dulawa, E., Palucki, J., Pilch-Kowalczyk, J., Rosiek, V., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Strzelczyk, J., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zgliczynski, W., and Kos-Kudla, B.

Subjects
Male, Disease Management, Small intestine, Appendix, Guidelines, Somatostatin analogues, Medical Oncology, Neuroendocrine Tumors, Endocrinology, Carcinoid syndrome, Radioisotope therapy, Neuroendocrine neoplasms, Intestinal Neoplasms, Humans, Female, Everolimus, PRRT, Poland, Societies, Medical
Abstract

This study presents the revised Polish guidelines regarding the management of patients suffering from neuroendocrine neoplasms (NENs) of the small intestine and appendix. The small intestine, especially the ileum, is the most common location for these neoplasms. Most are well differentiated and slow growing. Their symptoms may be atypical, which can result in delayed or accidental diagnosis. Appendicitis is usually the first manifestation of NEN in this location. Typical symptoms of carcinoid syndrome occur in approximately 20-30% of patients suffering from small intestinal NENs with distant metastases. The main cause of death in patients with carcinoid syndrome is carcinoid heart disease. The most useful laboratory test is the determination of chromogranin A, while concentration of 5-hydroxyindoleacetic acid is helpful in the diagnostics of carcinoid syndrome. For visualisation, ultrasound, computed tomography, magnetic resonance imaging, colonoscopy, video capsule endoscopy, double-balloon enteroscopy, and somatostatin receptor scintigraphy may be used. A detailed his-tological report is crucial for the proper diagnostics and therapy of NENs of the small intestine and appendix. The treatment of choice is surgical management, either radical or palliative. The pharmacological treatment of the hormonally active and non-active small intestinal NENs as well as NENs of the appendix is based on long-acting somatostatin analogues. In patients with generalised NENs of the small intestine in progress during the SSA treatment, with good expression of somatostatin receptors, the first-line treatment should be radio-isotope therapy, while targeted therapies, such as everolimus, should be considered afterwards. When the above therapies are exhausted, in certain cases chemotherapy may be considered.

Published
2017

31. Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms

Author

Capdevila, Jaume, Bodei, Lisa, Davies, Philippa, Gorbounova, Vera, Jensen, Robert T., Knigge, Ulrich P., Krejs, Guenter J., Krenning, Eric, O'Connor, Juan Manuel, Peeters, Marc, Rindi, Guido, Salazar, Ramon, Vullierme, Marie-Pierre, Pavel, Marianne E., Arnold, R., Bartsch, D., Baudin, E., Bodei, L., Borbath, I, Capdevila, J., Caplin, M., Chen, J., Costa, F., Couvelard, A., Cwikla, J. B., Davies, P., de Herder, W. W., Falconi, M., Falkerby, J., Fazio, N., Ferone, D., Frilling, A., Garcia-Carbonero, R., Glasberg, S., Gorbunova, V, Grossman, A., Hoersch, D., Jensen, R. T., Kaltsas, G., Kloeppel, G., Knigge, U. P., Kos-Kudla, B., Krejs, G. J., Krenning, E., Kulke, M., Lamberts, S. W. J., van Dijkum, Nieveen E., O'Connor, J. M., O'Toole, D., Pape, U. F., Partelli, S., Pavel, M. E., Ramage, J., Reed, N. Simon Beatson, Rindi, G., Rinke, A., Ruszniewski, P., Sorbye, H., Sundin, A., Scoazec, J. Y., Taal, B. G., Tiensuu, J. E., Toumpanakis, C., Valle, J., Vullierme, M. P., Welin, S., Wiedenmann, B., Capdevila, J, Bodei, L, Davies, P, Gorbounova, V, Jensen, Rt, Knigge, Up, Krejs, Gj, Krenning, E, O'Connor, Jm, Peeters, M, Rindi, G, Salazar, R, Vullierme, Mp, Pavel, Me, on behalf the ENETS 2016 Munich Advisory Board, Participant, Partelli, S, Falconi, M, Erasmus MC other, Internal Medicine, ENETS 2016 Munich Advisory Board, and Dr. Heinz-Horst Deichmann Stiftung

Subjects
Biomedical Research, Lung Neoplasms, Endocrinology, Diabetes and Metabolism, Metastasi, Lanreotide, Digestive System Neoplasms, Metastasis, 030218 nuclear medicine & medical imaging, Imaging, chemistry.chemical_compound, EVEROLIMUS, 0302 clinical medicine, Endocrinology, LANREOTIDE, Treatment options, TUMORS, Clinical Practice, Neuroendocrine Tumors, Unmet medical needs, SURVIVAL, ENETS 2016 Munich Advisory Board Participants, Life Sciences & Biomedicine, medicine.medical_specialty, 030209 endocrinology & metabolism, SUNITINIB, Endocrinology & Metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Drug Development, Internal medicine, medicine, Biomarkers, Tumor, Humans, Limited evidence, Intensive care medicine, Science & Technology, Endocrine and Autonomic Systems, business.industry, Neurosciences, 1103 Clinical Sciences, Biomarker, Neuroendocrine neoplasm, chemistry, Neuroendocrine neoplasms, Neurosciences & Neurology, Human medicine, Therapy, 1109 Neurosciences, business, Who classification, Biomarkers
Abstract

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Published
2019

32. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

Author

Capdevila, Jaume Bodei, Lisa Davies, Philippa Gorbounova, Vera Jensen, Robert T. Knigge, Ulrich P. Krejs, Guenter J. and Krenning, Eric O'Connor, Juan Manuel Peeters, Marc and Rindi, Guido Salazar, Ramon Vullierme, Marie-Pierre Pavel, Marianne E. Arnold, R. Bartsch, D. Baudin, E. Bodei, L. and Borbath, I Capdevila, J. Caplin, M. Chen, J. Costa, F. Couvelard, A. Cwikla, J. B. Davies, P. de Herder, W. W. Falconi, M. Falkerby, J. Fazio, N. Ferone, D. and Frilling, A. Garcia-Carbonero, R. Glasberg, S. Gorbunova, V and Grossman, A. Hoersch, D. Jensen, R. T. Kaltsas, G. and Kloeppel, G. Knigge, U. P. Kos-Kudla, B. Krejs, G. J. and Krenning, E. Kulke, M. Lamberts, S. W. J. van Dijkum, Nieveen E. O'Connor, J. M. O'Toole, D. Pape, U. F. and Partelli, S. Pavel, M. E. Peeters, M. Ramage, J. Reed, N. Simon Beatson Rindi, G. Rinke, A. Ruszniewski, P. and Sorbye, H. Sundin, A. Scoazec, J. Y. Taal, B. G. and Tiensuu, J. E. Toumpanakis, C. Valle, J. Vullierme, M. P. and Welin, S. Wiedenmann, B. ENETS 2016 Munich Advisory Board

Abstract

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Published
2019

33. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

Author

Falconi, M, Eriksson, B, Kaltsas, G, Bartsch, D K, Capdevila, J, Caplin, M, Kos-Kudla, B, Kwekkeboom, D, Rindi, G, Klöppel, G, Reed, N, Kianmanesh, R, Jensen, R T, Ferone, D, and Radiology & Nuclear Medicine

Subjects
Settore MED/08 - ANATOMIA PATOLOGICA, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, Non functional, Europe, Humans, Neuroendocrine Tumors, Pancreatic Neoplasms, MEDLINE, Disease, Guideline, Neuroendocrine tumors, Bioinformatics, medicine.disease, Pancreatic Neuroendocrine Neoplasm, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, 030220 oncology & carcinogenesis, Medicine, 030211 gastroenterology & hepatology, business
Abstract

Only advances that occurred from 2011–2014 that either strengthen the previous 2011 guidelines [1;2] or lead to changes or additional guidelines are reviewed here. Advances and modifications in the treatment of advanced metastatic disease is only briefly dealt with here as it is covered in a separate chapter, similar to the 2011 guideline format [3]. The format used here is the same as used in the 2011 guidelines with page references to the appropriate section inserted [1;2] and this document is meant as a supplement to these guidelines and does not reiterate all of the points made in the previous guidelines, only changes, supporting findings or modifications of the 2011 guidelines are thus covered here. As in the previous F-p-NET guidelines [1], the F-p-NETs will be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare functional p-NETs (RFTs) considered together and as a separate category (Annex 1 and Table 1). Table 1 Functional Pancreatic endocrine tumors [F-p-NET] syndromes

Published
2016
Full Text
View/download PDF

34. Pancreatic neuroendocrine neoplasms-management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Author

Kos-Kudla B., Rosiek V., Borowska M., Baldys-Waligorska A., Bednarczuk T., Blicharz-Dorniak J., Bolanowski M., Boratyn-Nowicka A., Cichocki A., Cwikla J. B., Falconi M., Foltyn W., Handkiewicz-Junak D., Hubalewska-Dydejczyk A., Jarzab B., Jarzab M., Junik R., Kajdaniuk D., Kaminski G., Kolasinska-Cwikla A., Kowalska A., Krol R., Krolicki L., Kunikowska J., Kusnierz K., Lampe P., Lange D., Lewczuk-Myslicka A., Lewinski A., Lipinski M., Londzin-Olesik M., Marek B., Nasierowska-Guttmejer A., Nowakowska-Dulawa E., Pilch-Kowalczyk J., Ruchala M., Sieminska L., Sowa-Staszczak A., Starzynska T., Steinhof-Radwanska K., Strzelczyk J., Sworczak K., Syrenicz A., Szawlowski A., Szczepkowski M., Wachula E., Zajecki W., Zemczak A., Zgliczynski W., Kos-Kudla, B., Rosiek, V., Borowska, M., Baldys-Waligorska, A., Bednarczuk, T., Blicharz-Dorniak, J., Bolanowski, M., Boratyn-Nowicka, A., Cichocki, A., Cwikla, J. B., Falconi, M., Foltyn, W., Handkiewicz-Junak, D., Hubalewska-Dydejczyk, A., Jarzab, B., Jarzab, M., Junik, R., Kajdaniuk, D., Kaminski, G., Kolasinska-Cwikla, A., Kowalska, A., Krol, R., Krolicki, L., Kunikowska, J., Kusnierz, K., Lampe, P., Lange, D., Lewczuk-Myslicka, A., Lewinski, A., Lipinski, M., Londzin-Olesik, M., Marek, B., Nasierowska-Guttmejer, A., Nowakowska-Dulawa, E., Pilch-Kowalczyk, J., Ruchala, M., Sieminska, L., Sowa-Staszczak, A., Starzynska, T., Steinhof-Radwanska, K., Strzelczyk, J., Sworczak, K., Syrenicz, A., Szawlowski, A., Szczepkowski, M., Wachula, E., Zajecki, W., Zemczak, A., and Zgliczynski, W.

Subjects
Functional, Non-functional, Therapy, Guidelines, Pancreatic neuroendocrine neoplasms, Diagnostics
Abstract

This article presents updated diagnostic and therapeutic guidelines for the management of pancreatic neuroendocrine tumours (PNEN), proposed by the Polish Network of Neuroendocrine Tumours. The guidelines contain new data received in the years 2013-2016, which confirm previous recommendations, and have led to modification of previous guidelines or have resulted in the formulation of new guidelines. Biochemical and imaging (anatomical and functional) tests are of great importance in diagnostics, as well as histopathological diagnosis to determine the management of PNEN patients, but they must be confirmed by an immunohistochemical examination. PNEN therapy requires collaboration among members of a multidisciplinary of specialists experienced in the management of these neoplasms. Surgery is the basic form of treatment in many cases. Further therapy requires a multidirectional procedure; therefore, the rules of biotherapy, peptide receptor radionuclide therapy, molecular targeted therapy, and chemotherapy are discussed.

Published
2017

35. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms

Author

Fave, G. D., Kwekkeboom, D. J., Cutsem, E. V., Rindi, G., Kos Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., Ruszniewski, P., Conference Anlauf M, B. C., Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., Fave, G. D., Kwekkeboom, D. J., Cutsem, E. V., Rindi, G., Kos Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., Ruszniewski, P., Radiology & Nuclear Medicine, Delle Fave G., Kwekkeboom DJ., Van Cutsem E., Rindi G., Kos-Kudla B., Knigge U., Sasano H., Tomassetti P., Salazar R., and Ruszniewski P.

Subjects
medicine.medical_specialty, Settore MED/06 - ONCOLOGIA MEDICA, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, MEDLINE, diagnosis/epidemiology/therapy, GUIDELINES, University hospital, ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms, Cellular and Molecular Neuroscience, Neuroendocrine Tumors, Endocrinology, Duodenal Neoplasms, diagnosis/epidemiology/therapy, Humans, Neuroendocrine Tumors, diagnosis/epidemiology/therapy, Stomach Neoplasms, Stomach Neoplasms, Internal medicine, medicine, Humans, business
Abstract

a Department of Digestive and Liver Disease, Ospedale Sant’Andrea, Rome , Italy; b Department of Oncology, Royal Free University UFR Bichat-Beaujon-Louis Mourier, Colombes , France; c Digestive Oncology, University Hospital Gasthuisberg/Leuven, Leuven , Belgium; d Institute of Pathology, Catholic University – Policlinic A. Gemelli, Rome , Italy; e Department of Endocrinology, Medical University of Silesia, Katowice , Poland; f Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen , Denmark; g Department of Pathology, Tohoku University Graduate School of Medicine, Sendai , Japan; h Department of Internal Medicine and Gastroenterology, St. Orsola Hospital, University of Bologna, Bologna , Italy; i Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; j Department of Gastroenterology, Beaujon Hospital, Clichy , France

Published
2012

36. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Author

M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller, M. Anlauf, B. Wiedenmann, R. Salazar, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, M., Pavel, E., Baudin, A., Couvelard, E., Krenning, K., Öberg, T., Steinmüller, M., Anlauf, B., Wiedenmann, R., Salazar, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., and Radiology & Nuclear Medicine

Subjects
medicine.medical_specialty, animal structures, Endocrinology, Diabetes and Metabolism, Intestinal Neoplasm, Neuroendocrine tumors, Biology, digestive system, Cellular and Molecular Neuroscience, Endocrinology, stomatognathic system, Internal medicine, Intestinal Neoplasms, medicine, Humans, Endocrine and Autonomic Systems, Liver Neoplasms, fungi, Midgut, Hindgut, Foregut, medicine.disease, Neuroendocrine Tumors, embryonic structures, Unknown primary, Neoplasms, Unknown Primary
Abstract

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Published
2012
Full Text
View/download PDF

37. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

Author

U. Pape, A. Perren, B. Niederle, D. Gross, T. Gress, F. Costa, R. Arnold, T. Denecke, U. Plöckinger, R. Salazar, A. Grossman, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, Erasmus MC other, U., Pape, A., Perren, B., Niederle, D., Gro, T., Gre, F., Costa, R., Arnold, T., Denecke, U., Plöckinger, R., Salazar, A., Grossman, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, General surgery, University hospital, Appendix, Appendiceal neoplasms, Neuroendocrine Tumors, Cellular and Molecular Neuroscience, Jejunum, Endocrinology, medicine.anatomical_structure, Appendiceal Neoplasms, Ileum, Internal medicine, Intestinal Neoplasms, neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas, medicine, Humans, business
Abstract

a Division of Hepatology and Gastroenterology, Department of Internal Medicine, Campus Virchow-Klinikum, Charite-Universitatsmedizin Berlin, Berlin , Germany; b Department of Pathology, Universitatsspital, Zurich , Switzerland; c Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna , Austria; d Department of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem , Israel; e Department of Internal Medicine, Philipps University, Marburg , Germany; f Hopital Sirio Libanes, Centro de Oncologia, Sao Paulo , Brazil; g Department of Radiology, Campus Virchow-Klinikum, Charite, University Medicine Berlin, Berlin , Germany; h Department of Oncology, Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; i Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford , UK

Published
2012
Full Text
View/download PDF

38. Consensus Guidelines Update for the Management of Functional p-NETs (F-p-NETs) and Non-Functional p-NETs (NF-p-NETs)

Author

FALCONI , MASSIMO, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT, all other Vienna Consensus Conference participants, Falconi, Massimo, Eriksson, B, Kaltsas, G, Bartsch, Dk, Capdevila, J, Caplin, M, Kos Kudla, B, Kwekkeboom, D, Rindi, G, Klöppel, G, Reed, N, Kianmanesh, R, Jensen, Rt, and all other Vienna Consensus Conference, Participants

Published
2016

39. Recommendations for management of patients with neuroendocrine liver metastases

Author

Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan yee Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, Adam, R, Akerstrom, G, Belghiti, J, Breitenstein, S, Clavien, Pa, Frilling, A, Gustafsson, B, Krenning, E, Modlin, Im, Norton, J, Öberg, K, Poston, G, Ruszniewski, P, Tait, P, Toogood, G, Russell, C, Bouvier, C, Jarecki, A, Klersy, C, Lau, Wj, Siegler, M, Rindi, G, Kidd, M, Vilgrain, V, Baum, Rp, Heaton, N, Garden, J, Fan, St, Van Gulik, T, Sipperstein, A, Kwekkeboom, D, Caplin, M, Lawrence, B, de Herder, W, Ito, T, Perren, A, Davidson, B, Klimstra, Ds, Kloppel, G, Scarpa, A, Meyer, T, Knuth, A, Chen, H, Van Cutsem, E, Pavel, Me, Kos Kudla, B, Conlon, K, Imamura, M, Kaltsas, G, Broering, D, Wiedenmann, B, Al Nahhas, A, Lodge, P, Cosimelli, M, Grazi, G, Tang, Lh, Salazar, R, Grossman, Ab, Dejong, C, Gores, G, Nagorney, Dm, Mazzaferro, V, Jensen, R, Lesurtel, M, Falconi, M, Hellmann, P, O'Toole, D, Olauson, M, Le Treut, Y, Burroughs, Ak, Valle, J, Kianmanesch, R, Sowa Staszczak, A, Milicevic, M, Lencioni, RICCARDO ANTONIO, Ramage, J, Sangro, B, Kennedy, A, Bester, L, Salem, R, Sharma, R, Parks, R, Bodei, L, Muller Brand, J, Kvols, L, Manas, D, Ramos, J, Wasan, H., Frilling, Andrea, Modlin Irvin, M., Kidd, Mark, Russell, Christopher, Breitenstein, Stefan, Salem, Riad, Kwekkeboom, Dik, Lau Wan, Yee, Klersy, Catherine, Vilgrain, Valerie, Davidson, Brian, Siegler, Mark, Caplin, Martyn, Solcia, Enrico, Schilsky, Richard, Falconi, Massimo, Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan-yee, Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, for the Working Group on Neuroendocrine Liver Metastases,, Grazi, G., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
medicine.medical_specialty, Biopsy, MEDLINE, clinical practice guidelines, hepatic metastases, prognostic factors, surgical management, Neuroendocrine tumors, surgical management, Systemic therapy, NO, medicine, Hepatectomy, Humans, hepatic metastases, Intensive care medicine, medicine.diagnostic_test, business.industry, Liver Neoplasms, prognostic factors, Interventional radiology, medicine.disease, Neoplastic Cells, Circulating, Neoadjuvant Therapy, Surgery, Clinical Practice, Neuroendocrine Tumors, Oncology, Genomic information, business, Working group, clinical practice guidelines
Abstract

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research. © 2014 Elsevier Ltd.

Published
2014
Full Text
View/download PDF

40. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Author

Knigge, U, Capdevila, J, Bartsch, D K, Baudin, E, Falkerby, J, Kianmanesh, R, Kos-Kudla, B, Niederle, B, Nieveen van Dijkum, E, O'Toole, D, Pascher, A, Reed, N, Sundin, A, Vullierme, M-P, Ferone, D, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Other Research, and Surgery

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, MEDLINE, TNM staging, 030209 endocrinology & metabolism, 610 Medicine & health, 5-Hydroxyindoleacetic acid, Neuron specific enolase, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Documentation, Neuroendocrine tumor, Internal medicine, medicine, Neuroendocrine carcinoma, Neuroendocrine neoplasm, Follow up, Chromogranin A, NT-pro-brain natriuretic peptide, Functional imaging, Somatostatin receptor imaging, Endocrine and Autonomic Systems, business.industry, 030220 oncology & carcinogenesis, TNM Staging, 570 Life sciences, biology, business
Abstract

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing. (C) 2017 S. Karger AG, Basel

Published
2017
Full Text
View/download PDF

41. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- A nd Perioperative Therapy in Patients with Neuroendocrine Tumors

Author

Kaltsas, G. Caplin, M. Davies, P. Ferone, D. Garcia-Carbonero, R. Grozinsky-Glasberg, S. Hörsch, D. Tiensuu Janson, E. Kianmanesh, R. Kos-Kudla, B. Pavel, M. Rinke, A. Falconi, M. De Herder, W.W.

Subjects
endocrine system, endocrine system diseases, digestive system diseases
Abstract

Neuroendocrine tumors of the small intestine are the most common causes of the carcinoid syndrome. Carcinoid heart disease occurs in more than half of the patients with the carcinoid syndrome. Patients with carcinoid heart disease who need to undergo surgery should also undergo preoperative evaluation by an expert cardiologist. Treatment with long-acting somatostatin analogs aims at controlling the excessive hormonal output and symptoms related to the carcinoid syndrome and at preventing a carcinoid crisis during interventions. Patients with a gastrinoma require pre- A nd postoperative treatment with high doses of proton pump inhibitors. Patients with a glucagonoma require somatostatin analog treatment and nutritional supplementation. Patients with a VIPoma also require somatostatin analog treatment and intravenous fluid and electrolyte therapy. Insulinoma patients generally require intravenous glucose infusion prior to operation. In patients with localized operable insulinoma, somatostatin analog infusion should only be considered after the effect of this therapy has been electively studied. © 2017 The Author(s).

Published
2017

42. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography

Author

Plöckinger, U., Gustafsson, B., Ivan, D., Szpak, W., Davar, J., Åkerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. J., Costa, F., Couvelard, A., Herder, W. D., Fave, G. D., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Hyrdel, R., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., O'Connor, J., O'Toole, D., Pape, U. F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Carcinoid tumors, MEDLINE, Carcinoid Heart Disease, carcinoid syndrome, Diagnostic accuracy, Disease, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, cancer diagnosis, Internal medicine, Humans, echocardiography, Medicine, human, medical society, conference paper, medical documentation, Endocrine and Autonomic Systems, business.industry, practice guideline, Medical practice, diagnostic accuracy, medical practice, neuroendocrine tumor, patient information, priority journal, medicine.disease, Medical documents, Neuroendocrine Tumors, business, Carcinoid syndrome
Abstract

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : echocardiography.

Published
2009
Full Text
View/download PDF

45. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms : Follow-Up and Documentation

Author

Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, Jenny, Kianmanesh, R., Kos-Kudla, B., Niederle, B., van Dijkum, E. Nieveen, O'Toole, D., Pascher, A., Reed, N., Sundin, Anders, Vullierme, M. -P, Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, Jenny, Kianmanesh, R., Kos-Kudla, B., Niederle, B., van Dijkum, E. Nieveen, O'Toole, D., Pascher, A., Reed, N., Sundin, Anders, and Vullierme, M. -P

Abstract

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

Published
2017
Full Text
View/download PDF

46. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- A nd Perioperative Therapy in Patients with Neuroendocrine Tumors

Author

Kaltsas, G. (Gregory), Caplin, M. (Martyn), Davies, P. (Philippa), Ferone, D. (Diego), Garcia-Carbonero, R. (Rocio), Grozinsky-Glasberg, S. (Simona), Hörsch, D. (D.), Tiensuu Janson, E. (Eva), Kianmanesh, R., Kos-Kudla, B. (Beata), Pavel, M. (Marianne), Rinke, A. (Anja), Falconi, M. (Massimo), Herder, W.W. (Wouter) de, Kaltsas, G. (Gregory), Caplin, M. (Martyn), Davies, P. (Philippa), Ferone, D. (Diego), Garcia-Carbonero, R. (Rocio), Grozinsky-Glasberg, S. (Simona), Hörsch, D. (D.), Tiensuu Janson, E. (Eva), Kianmanesh, R., Kos-Kudla, B. (Beata), Pavel, M. (Marianne), Rinke, A. (Anja), Falconi, M. (Massimo), and Herder, W.W. (Wouter) de

Abstract

Neuroendocrine tumors of the small intestine are the most common causes of the carcinoid syndrome. Carcinoid heart disease occurs in more than half of the patients with the carcinoid syndrome. Patients with carcinoid heart disease who need to undergo surgery should also undergo preoperative evaluation by an expert cardiologist. Treatment with long-acting somatostatin analogs aims at controlling the excessive hormonal output and symptoms related to the carcinoid syndrome and at preventing a carcinoid crisis during interventions. Patients with a gastrinoma require pre- A nd postoperative treatment with high doses of proton pump inhibitors. Patients with a glucagonoma require somatostatin analog treatment and nutritional supplementation. Patients with a VIPoma also require somatostatin analog treatment and intravenous fluid and electrolyte therapy. Insulinoma patients generally require intravenous glucose infusion prior to operation. In patients with localized operable insulinoma, somatostatin analog infusion should only be considered after the effect of this therapy has been electively studied.

Published
2017
Full Text
View/download PDF

47. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms:Follow-Up and Documentation

Author

Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen Van Dijkum, E., O'Toole, D., Pascher, A., Reed, N., Sundin, A., Vullierme, M. P., Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen Van Dijkum, E., O'Toole, D., Pascher, A., Reed, N., Sundin, A., and Vullierme, M. P.

Abstract

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

Published
2017

48. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Author

Kaltsas, G, Caplin, M, Davies, P, Ferone, D, Garcia-Carbonero, R, Grozinsky-Glasberg, S, Horsch, D, Janson, ET, Kianmanesh, R, Kos-Kudla, B, Pavel, M, Rinke, A, Falconi, M, de Herder, W.W., Kaltsas, G, Caplin, M, Davies, P, Ferone, D, Garcia-Carbonero, R, Grozinsky-Glasberg, S, Horsch, D, Janson, ET, Kianmanesh, R, Kos-Kudla, B, Pavel, M, Rinke, A, Falconi, M, and de Herder, W.W.

Published
2017

49. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes

Author

Jensen, R. T., Cadiot, G., Brandi, M. L., W. W., De, Kaltsas, G., Komminoth, P., Scoazec, J., Salazar, R., Sauvanet, A., Kianmanesh, R., Conference Anlauf M, B. C., Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., R. T., Jensen, G., Cadiot, M. L., Brandi, W. W., De, G., Kaltsa, P., Komminoth, J., Scoazec, R., Salazar, A., Sauvanet, R., Kianmanesh, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., and Internal Medicine

Subjects
ENETS Consensus Guidelines, medicine.medical_specialty, Pathology, Endocrinology, Diabetes and Metabolism, ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes, Hypoglycemia, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, Humans, Pancreatic polypeptide, MEN1, Multiple endocrine neoplasia, biology, Endocrine and Autonomic Systems, business.industry, Chromogranin A, medicine.disease, Pancreatic Neoplasms, Neuroendocrine Tumors, medicine.anatomical_structure, biology.protein, Pancreas, business, Carcinoid syndrome
Abstract

Pancreatic endocrine tumors (p-NETs) include both pancreatic neuroendocrine tumors (p-NETs) associated with a functional syndrome (functional p-NETs) or those associated with no distinct clinical syndrome (non-functional p-NETs) [1,2,3,4]. Non-functional p-NETs frequently secrete pancreatic polypeptide, chromogranin A, neuron-specific enolase, human chorionic gonadotrophin subunits, calcitonin, neurotensin or other peptides, but they do not usually produce specific symptoms and thus are considered clinically to be non-functional tumors [2,3,5,6,7]. Only the functional p-NETs will be considered in this section. The two most common functional p-NETs (gastrinomas, insulinomas) are considered separately, whereas the other well-described and possible rare functional p-NETs are considered together as a group called rare functional p-NETs (RFTs) (table ​(table1)1) [1,2,3,4]. Table 1 Functional pancreatic endocrine tumor (PET) syndromes Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome (ZES). ZES is characterized by gastric acid hypersecretion resulting in severe peptic disease (peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)) [8,9,10]. In this section, ZES due to both duodenal and pancreatic gastrinomas will be covered together because clinically they are similar [8,10]. Specific points related to gastrinomas associated with the genetic syndrome of Multiple Endocrine Neoplasia type 1 (MEN1) (25% of cases) will also be mentioned [11,12]. Insulinomas are neuroendocrine neoplasms located in the pancreas that secrete insulin, which causes a distinct syndrome characterized by symptoms due to hypoglycemia [2,13,14,15]. The symptoms are typically associated with fasting and the majority of patients have symptoms secondary to hypoglycemic central nervous system (CNS) effects (headaches, confusion, visual disturbances, etc.) or due to catecholamine excess secondary to hypoglycemia (sweating, tremor, palpitations, etc.) [2,3,13,14,15]. RFTs can occur in the pancreas or in other locations (VIPomas, somatostatinomas, GRHomas, ACTHomas, p-NETs causing carcinoid syndrome or hypercalcemia (PTHrp-omas)) (table ​(table1)1) [1,2,3,4,5,7]. Each of the established RFT syndromes is associated with a distinct clinical syndrome reflecting the actions of the ectopically secreted hormone. Other RFTs are listed as causing a possible specific syndrome either because there are too few cases or there is disagreement about whether the described features are actually a distinct syndrome (table ​(table1)1) [1,2,3,4,5,7].

Published
2012

50. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms

Author

M. Caplin, A. Sundin, O. Nillson, R. P. Baum, K. J. Klose, F. Kelestimur, U. Plöckinger, M. Papotti, R. Salazar, A. Pascher, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, M., Caplin, A., Sundin, O., Nillson, R. P., Baum, K. J., Klose, F., Kelestimur, U., Plöckinger, M., Papotti, R., Salazar, A., Pascher, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms, stomatognathic diseases, Cellular and Molecular Neuroscience, Neuroendocrine Tumors, Endocrinology, Internal medicine, medicine, Humans, business, Colorectal Neoplasms
Abstract

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : colorectal neuroendocrine neoplasms

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results